Anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody and use thereof to treat disease
US12378309B2 · kind B2 · utility
0Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 1, 2024 |
| Grant date | Aug 5, 2025 |
| Priority date | — |
| Expiry date | Mar 1, 2044 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Provided in the present invention are an anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody and the use thereof. The monoclonal antibody has high affinity for human TSLP, has a neutralizing activity, and can be used for preventing or treating TSLP-mediated diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.